<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia : Publica&#xE7;a&#x30B;o Oficial da Sociedade Brasileira de Pneumologia e Tisilogia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23503494</article-id>
      <article-id pub-id-type="pmc">4075794</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37132013000100016</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter To The Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Incremental low doses of amrubicin for the treatment of
bone marrow metastasis in small cell lung cancer</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Baixas doses incrementais de amrubicina para o tratamento de met&#xE1;stase
de medula &#xF3;ssea em c&#xE2;ncer de pulm&#xE3;o de pequenas c&#xE9;lulas</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Asai</surname>
            <given-names>Nobuhiro</given-names>
          </name>
          <role>Resident</role>
          <aff>Kameda Medical Center, Kamogawa, Japan, Kameda Medical Center, Kamogawa, Japan</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ohkuni</surname>
            <given-names>Yoshihiro</given-names>
          </name>
          <role>Chief</role>
          <aff>Kameda Medical Center, Kamogawa, Japan, Kameda Medical Center, Kamogawa, Japan</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsuda</surname>
            <given-names>Masanori</given-names>
          </name>
          <role>Chief</role>
          <aff>Kameda Medical Center, Kamogawa, Japan, Kameda Medical Center, Kamogawa, Japan</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Narita</surname>
            <given-names>Makoto</given-names>
          </name>
          <role>Chief</role>
          <aff>Kameda Medical Center, Kamogawa, Japan, Kameda Medical Center, Kamogawa, Japan</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kaneko</surname>
            <given-names>Norihiro</given-names>
          </name>
          <role>Chief</role>
          <aff>Kameda Medical Center, Kamogawa, Japan, Kameda Medical Center, Kamogawa, Japan</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Feb</season>
        <year>2013</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2013</year>
      </pub-date>
      <volume>39</volume>
      <issue>1</issue>
      <fpage>108</fpage>
      <lpage>110</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>4</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>06</day>
          <month>6</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <counts>
        <fig-count count="2"/>
        <ref-count count="10"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>To the Editor:</title>
      <p>Lung cancer remains the leading cause of cancer death, and approximately 13% of all
patients with lung cancer are diagnosed as having small cell lung cancer
(SCLC).<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup> Although SCLC is highly sensitive to first-line chemotherapy
and radiation therapy, most SCLC patients experience relapse within two years and die
from systemic metastasis.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup> Despite the fact that bone marrow is well
known to be one of the organs affected by metastasis,<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup> there is no
established treatment for bone marrow metastasis of SCLC.</p>
      <p>To our knowledge, this is the first case report of extensive disease SCLC (ED-SCLC) and
bone marrow metastasis successfully treated with low-dose amrubicin alone. A 71-year-old
male patient presenting with a one-week history of general fatigue and eventual
disorientation was referred to us. Laboratory tests revealed hyponatremia (104 mEq/L)
and pancytopenia (white blood cells, 1,900/&#xB5;L; hemoglobin, 8.0 g/dL; and platelet count,
1.9 &#xB5;g/mL). In addition, there was an abnormal shadow with multiple swollen lymph nodes
on chest X-ray and CT scans (<xref ref-type="fig" rid="f01">Figure 1</xref>). Bone
marrow aspiration revealed bone marrow metastasis of SCLC (<xref ref-type="fig" rid="f02">Figure 2</xref>). He was diagnosed with ED-SCLC (tumor-node-metastasis
staging system cT4N3M1, stage IV) and bone marrow metastasis. Enhanced magnetic
resonance imaging of the brain showed no evidence of brain metastasis. Treatment was
started with a low dose (30 mg/m<sup>2</sup>) of amrubicin and platelet transfusion
(100,000 units). His pancytopenia and disorientation improved after two courses of
amrubicin. We administered escalating doses (from 30 to 35 mg/m<sup>2</sup>) of
amrubicin based on the performance status of the patient. A total of six courses of
amrubicin were administered (two and four cycles of 30 mg/m<sup>2</sup> and 35
mg/m<sup>2</sup>, respectively), resulting in complete response, as determined by
Response Evaluation Criteria in Solid Tumors. After a six-month follow-up period, the
SCLC remained in complete remission.</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>In A, chest X-ray showing bilateral hilar lymphadenopathy and slight
effusion on the right. In B, CT scan of the chest showing multiple swollen
lymph nodes and subpleural nodules.</title></caption><graphic xlink:href="1806-3713-jbpneu-39-01-00108-gf01"/></fig>
</p>
      <p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>In A, bone marrow aspirate showing metastasis of small cell lung cancer
(H&amp;E; magnification, &#xD7;400). In B, tumor cells testing positive for
anti-cytokeratin (AE1/AE3; immunohistochemical staining; magnification, &#xD7;400).
In C, tumor cells testing positive for thyroid transcription factor-1 (TTF-1;
immunohistochemical staining; magnification, &#xD7;400). In D, tumor cells testing
positive for synaptophysin (immunohistochemical staining; magnification,
&#xD7;400).</title></caption><graphic xlink:href="1806-3713-jbpneu-39-01-00108-gf02"/></fig>
</p>
      <p>Amrubicin is a fully synthetic 9-aminoanthracycline, which is converted in the body to
amrubicinol by reduction of the ketone in position 13. Amrubicinol has a higher
antitumor activity than does the parent molecule. Although they are classified as
anthracycline agents, amrubicin and amrubicinol exert cytotoxic effects as DNA
topoisomerase II inhibitors rather than as DNA intercalators.<sup>(</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>-</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> In Japan,
a phase II study showed the results of intravenous administration of single-agent
amrubicin at 40 mg/m<sup>2</sup> for three consecutive days in previously treated SCLC
patients. The overall response rates were 52% and 50% in cases of sensitive SCLC and
refractory/relapsed SCLC, respectively, and the mean survival times were 11.6 and 10.3
months.<sup>(</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup> That study demonstrated that amrubicin was superior to
topotecan in terms of response rates and overall survival. However, grade 3-4
neutropenia, thrombocytopenia, anemia, and febrile neutropenia were seen in 83%, 20%,
33%, and 5% of the patients, respectively.<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup> The efficacy of low-dose
amrubicin therapy has recently been reported, amrubicin having been reported as a
first-line chemotherapeutic agent for the elderly<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup> and as a third-line
chemotherapeutic agent for refractory/relapsed SCLC.<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Despite its
hematologic toxicity, amrubicin is safe and effective when dose modulation techniques
are used on the basis of the condition of the patient.</p>
      <p>The therapy for bone marrow metastasis has yet to be established. Best supportive care
has been commonly prescribed in our practice. However, incremental doses of amrubicin
can be used for treating the disease.</p>
      <p>One limitation was the fact that the dose modulation of amrubicin was based on the
condition of the patient as assessed by the attending physician. This protocol has yet
to be established.</p>
      <p>In conclusion, we successfully treated a patient with SCLC and bone marrow metastasis.
The use of amrubicin in isolation can be useful in the treatment of ED-SCLC with bone
marrow metastasis. Further investigations are necessary.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful for the diligent and thorough critical reading of our manuscript by Mr.
John Wocher, Executive Vice President and Director, International Affairs/International
Patient Services at Kameda Medical Center, Japan.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Govindan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Page</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Morgensztern</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Read</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tierney</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vlahiotis</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Changing epidemiology of small-cell lung cancer in the
United States over the last 30 years: analysis of the surveillance, epidemiologic,
and end results database</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <issue>28</issue>
          <fpage>4539</fpage>
          <lpage>4544</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2005.04.4859">http://dx.doi.org/10.1200/JCO.2005.04.4859</ext-link>
          <pub-id pub-id-type="pmid">17008692</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nishiwaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kawahara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Negoro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sugiura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Irinotecan plus cisplatin compared with etoposide plus
cisplatin for extensive small-cell lung cancer</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>346</volume>
          <issue>2</issue>
          <fpage>85</fpage>
          <lpage>91</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa003034">http://dx.doi.org/10.1056/NEJMoa003034</ext-link>
          <pub-id pub-id-type="pmid">11784874</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El Maalouf</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rodier</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Faivre</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Raymond</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Could we expect to improve survival in small cell lung
cancer?</article-title>
          <source>Lung Cancer</source>
          <year>2007</year>
          <volume>57</volume>
          <issue>Suppl 2</issue>
          <fpage>S30</fpage>
          <lpage>S34</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0169-5002(07)70425-7">http://dx.doi.org/10.1016/S0169-5002(07)70425-7</ext-link>
          <pub-id pub-id-type="pmid">17686444</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Govindan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Page</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Morgensztern</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Read</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tierney</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vlahiotis</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Changing epidemiology of small-cell lung cancer in the
United States over the last 30 years: analysis of the surveillance, epidemiologic,
and end results database</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <issue>28</issue>
          <fpage>4539</fpage>
          <lpage>4544</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2005.04.4859">http://dx.doi.org/10.1200/JCO.2005.04.4859</ext-link>
          <pub-id pub-id-type="pmid">17008692</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Onoda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Masuda</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Seto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Eguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takiguchi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Isobe</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase II trial of amrubicin for treatment of refractory
or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study
0301</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <issue>34</issue>
          <fpage>5448</fpage>
          <lpage>5453</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2006.08.4145">http://dx.doi.org/10.1200/JCO.2006.08.4145</ext-link>
          <pub-id pub-id-type="pmid">17135647</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohe</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Minato</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bungo</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vitro evaluation of the new anticancer agents KT6149,
MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant
human cancer cell lines</article-title>
          <source>Cancer Res</source>
          <year>1989</year>
          <volume>49</volume>
          <issue>15</issue>
          <fpage>4098</fpage>
          <lpage>4102</lpage>
          <pub-id pub-id-type="pmid">2472873</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Obara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Imagawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Noguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagasawa</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Hematological aspects of a novel 9-aminoanthracycline,
amrubicin</article-title>
          <source>Cancer Sci</source>
          <year>2003</year>
          <volume>94</volume>
          <issue>12</issue>
          <fpage>1104</fpage>
          <lpage>1106</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1349-7006.2003.tb01407.x">http://dx.doi.org/10.1111/j.1349-7006.2003.tb01407.x</ext-link>
          <pub-id pub-id-type="pmid">14662027</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>von Pawel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ardizzoni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thatcher</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Crofts</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wissel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dane</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The relationship between treatment-free interval (TFI)
and outcomes to therapy in patients with relapsed small cell lung cancer (SCLC): a
review of 631 patients treated with iv topotecan in 6 studies</article-title>
          <source>Lung Cancer</source>
          <year>2003</year>
          <volume>41</volume>
          <fpage>S235</fpage>
          <lpage>S235</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0169-5002(03)92536-0">http://dx.doi.org/10.1016/S0169-5002(03)92536-0</ext-link>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Igawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ueda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ono</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsuya</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluation of the recommended dose and efficacy of
amrubicin as second- and third-line chemotherapy for small cell lung
cancer</article-title>
          <source>J Thorac Oncol</source>
          <year>2007</year>
          <volume>2</volume>
          <issue>8</issue>
          <fpage>741</fpage>
          <lpage>744</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/JTO.0b013e31811f46f0">http://dx.doi.org/10.1097/JTO.0b013e31811f46f0</ext-link>
          <pub-id pub-id-type="pmid">17762341</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ohkuni</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsunuma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nakashima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iwasaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kaneko</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of amrubicin for the elderly
patients with refractory relapsed small cell lung cancer as third-line
chemotherapy</article-title>
          <source>J Cancer Res Ther</source>
          <year>2012</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>266</fpage>
          <lpage>271</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4103/0973-1482.98983">http://dx.doi.org/10.4103/0973-1482.98983</ext-link>
          <pub-id pub-id-type="pmid">22842373</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
